Sanvar Salvation May Lie In Reanalyzing Data From Flawed Trial, Panel Says
Executive Summary
Debiovision's next step for its acute esophageal bleeding drug Sanvar (vapreotide) should be to go back and reanalyze the existing data from its pivotal trial before attempting additional trials to show efficacy for the treatment
You may also be interested in...
Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.